Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2024-02-07 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民集团关于收到政府补助的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the receipt of government subsidies over a specified period. It details the amounts, types of subsidies (asset-related and income-related), and their impact on the company's profit and loss for the periods mentioned. The document is relatively short (1938 characters) and focuses on financial impacts of government grants rather than presenting comprehensive financial statements or full financial performance reports. It does not contain full financial statements or detailed management analysis, nor is it a certification or a regulatory compliance filing. It is an announcement of a specific financial event (government subsidies) affecting the company's earnings. This type of announcement fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories. Therefore, the classification is RNS with high confidence.
2024-02-07 Chinese
健民集团关于对外投资暨关联交易的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 健民药业集团股份有限公司 regarding the progress of an external investment and related party transactions. It details the investment amounts, fund structures, and related party relationships. The document is relatively short (1935 characters) and focuses on disclosing investment progress and associated risks, typical of a capital or financing update. There is no indication that this is a full financial report, audit, or earnings release. It is not a voting result, management change, or legal proceeding. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2024-01-03 Chinese
湖北得伟君尚律师事务所关于健民药业集团股份有限公司2023年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of a company's 2023 second extraordinary general meeting of shareholders. It details the legality and validity of the meeting process and voting results. The document does not contain financial statements or performance data, nor is it a report of financial results or management discussion. It is a legal opinion related to a shareholders' meeting, specifically focusing on the voting results and their legality. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2480 characters, which is relatively short but contains substantive content about voting results, not just an announcement of a report publication or a regulatory filing. Hence, the classification is DVA with high confidence.
2023-12-25 Chinese
健民集团2023年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 second extraordinary shareholders' meeting of the company. It includes information about the meeting date, location, attendance, voting results on various proposals, and legal opinions from lawyers witnessing the meeting. The content focuses on the voting outcomes and procedural compliance of the shareholders' meeting. There is no indication that this is a full annual or interim report, audit report, earnings release, or other financial report. It is not a proxy solicitation or a presentation. The document is clearly an official declaration of voting results from a shareholders' meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters but contains substantive voting data, so it is not merely a report publication announcement. Therefore, the correct classification is DVA with high confidence.
2023-12-25 Chinese
健民集团第十届董事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by the company 健民药业集团股份有限公司. It details the approval of a donation proposal by the board of directors, including voting results. There is no financial report, audit, or detailed management discussion present. The content focuses on a board decision rather than a report or presentation. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board. The document length is short and it is not an announcement of a report publication or regulatory filing. Therefore, the classification is MANG with high confidence.
2023-12-25 Chinese
健民集团关于对外捐赠的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company's board regarding an external donation of pharmaceutical products to support earthquake relief efforts. It details the donation recipient, the value and purpose of the donation, and the terms of the donation agreement. There is no financial report, earnings data, management discussion, or regulatory filing content. The document is a specific announcement about a corporate social responsibility action (donation) rather than a financial or governance report. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is also not a regulatory filing or a report publication announcement. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-12-25 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.